Analysis of serum epithelium mesenchymal system marker for advanced or metastatic breast cancer treated with Eribuli
Not Applicable
- Conditions
- Advanced or metastatic breast cancer
- Registration Number
- JPRN-UMIN000027714
- Lead Sponsor
- Breast Surgery, Osaka Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. serious complication or past history: with symptomatic heart failure, ischemic heart disease within 6 months, liver cirrhosis, psychological disorder treated by antipsychotic drug, uncontrolable diabetes, etc 2. active infection 3. The anamnesis of the hypersensitivity to Eribulin 4. peripheral neuropathy greater than Grade 3 5. male breast cancer 6. under pregnancy or breast-feeding, and possibility (will) of pregnancy. 7. with doctors decision for exclusion
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison between change of serum epithelium mesenchymal system marker and clinical response after 3 cycles of Eribulin
- Secondary Outcome Measures
Name Time Method Objective Response Rate, Duration of Response, Progression free survival, Overall survival, Safety